ERT Integrates Asthma Measurement Device
Solution optimizes Fractional exhaled Nitric Oxide collection for improved data quality, site efficiency, and patient guidance
PHILADELPHIA – May 17, 2016 –– ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced it has successfully integrated the market-leading Fractional exhaled Nitric Oxide (FeNO) measurement device by Aerocrine-a Circassia subsidiary- into ERT’s diagnostic platform for spirometry, ECG and home monitoring for centralized clinical trials. NIOX VERO is Circassia’s FeNO solution, and it integrates with ERT’s market-leading platform, MasterScope™. The integrated solution is available immediately for clinical trials. “We are pleased to offer NIOX VERO integration for our biopharmaceutical customers,” said Achim Schülke, Executive Vice President, Respiratory Solutions at ERT. “By automating workflows with MasterScope, clinical trial sponsors will benefit from enhanced FeNO quality monitoring, protocol compliance, and patient performance as well as reduced investigative site burden.” Patients with allergic airway inflammation have higher than normal levels of nitric oxide in their exhaled breath. By measuring FeNO in accordance with American Thoracic Society and European Respiratory Society guidelines, clinicians can evaluate and compare allergic airway inflammation in patients with underlying asthma. “We are pleased to continue our ongoing partnership with ERT and to collaborate on solutions that improve efficiencies and outcomes for asthma patients, clinical study investigators and sponsors,” said Linda Szyper, Circassia’s Chief Commerical Officer. Supported on MasterScope, NIOX VERO and previous generation NIOX MINO® are cleared by the FDA and approved for use in global trials by many worldwide regulators. For more information on ERT’s suite of Respiratory Solutions, visit
http://www.ert.com/respiratory
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
About Circassia
Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners. For more information on Circassia please visit
www.circassia.com
.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
